Cidara Therapeutics

Founded 2012 · Biotech · Acquired

Rezafungin, a long-acting echinocandin antifungal therapeutic

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cidara.com

Sector: Biotech
Founded: 2012
Latest Form D: $240M, May 2024
Total capital: $407M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $349M; 7 Form D · last May 2024; 30 months since last filing
Federal contracts: $58.1M; 1 award · Health and Human S; Rank in Biotech#14 of 4373
Granted patents: 16; 24 pending · first 2015; Rank in peer group#105 of 1449

Capital timeline

Latest events

Sep 2025Federal contractHealth and Human S · Development Of CD388 As A Long-lasting Prophylactic Anti-viral Option For Protection Against The Health Impacts Caused By Influenza$58.1M
May 2024Private capital raisedForm D · SEC · 7th filing$240M
Sep 2019Private capital raisedForm D · SEC · 6th filing$9M
May 2018Private capital raisedForm D · SEC · 5th filing$1.6M
Oct 2017Private capital raisedForm D · SEC · 4th filing$20.2M
Feb 2015Private capital raisedForm D · SEC · 3rd filing$42M
Jun 2014Private capital raisedForm D · SEC · 2nd filing$30.3M
Jun 2014Private capital raisedForm D · SEC · 1st filing$6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#105 · top 7%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Bonnie Bassler, Ph.D.DirectorNamed in SEC Form D filings
Carin Canale-TheakstonDirectorNamed in SEC Form D filings
Chrysa R MineoDirectorNamed in SEC Form D filings
Dan BurgessDirectorNamed in SEC Form D filings
Daniel D. BurgessDirectorNamed in SEC Form D filings
Daniel D. BurgessDirectorNamed in SEC Form D filings

Show all 35 people

David R GollaherDirectorNamed in SEC Form D filings
Dirk ThyeExecutive OfficerNamed in SEC Form D filings
James R LevineExecutive OfficerNamed in SEC Form D filings
James Merson, Ph.D.DirectorNamed in SEC Form D filings
Jeffrey SteinExecutive Officer, DirectorNamed in SEC Form D filings
Jeffrey Stein, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
Jessica R OienExecutive OfficerNamed in SEC Form D filings
Ken BartizalExecutive OfficerNamed in SEC Form D filings
Kevin ForrestExecutive OfficerNamed in SEC Form D filings
Kevin JudiceDirectorNamed in SEC Form D filings
Laura Tadvalkar, Ph.D.DirectorNamed in SEC Form D filings
Leslie Tari, Ph.D.Executive OfficerNamed in SEC Form D filings
Matthew R OnaitisExecutive OfficerNamed in SEC Form D filings
Neil R AbdollahianExecutive OfficerNamed in SEC Form D filings
Nina KjellsonDirectorNamed in SEC Form D filings
Patrick HeronDirectorNamed in SEC Form D filings
Paul DaruwalaExecutive OfficerNamed in SEC Form D filings
Preetam Shah, Ph.D.Executive OfficerNamed in SEC Form D filings
Robert J PerezDirectorNamed in SEC Form D filings
Ryan SpencerDirectorNamed in SEC Form D filings
Scott M RocklageDirectorNamed in SEC Form D filings
Shane WardExecutive OfficerNamed in SEC Form D filings
Steve ElmsDirectorNamed in SEC Form D filings
Taylor R SandisonExecutive OfficerNamed in SEC Form D filings
Taylor Sandison, M.D.Executive OfficerNamed in SEC Form D filings
Ted SchroederDirectorNamed in SEC Form D filings
Theodore R. SchroederDirectorNamed in SEC Form D filings
Theodore R SchroederDirectorNamed in SEC Form D filings
Timothy R FransonDirectorNamed in SEC Form D filings

What it has protected

USPTO · 16 granted of 40

Apr 23, 2026PendingCompositions And Methods For The Treatment Of Viral InfectionsUSPTOApplication 19277976
Mar 10, 2026GrantedCompositions And Methods For The Treatment Of Viral InfectionsUSPTOUS 12,569,565
Jan 1, 2026PendingFc Conjugates Including An Inhibitor Of CD73 And Uses ThereofUSPTOApplication 18880895

Show all 40 patent records

Compositions And Methods For The Treatment Of Viral InfectionsApr 23, 2026 · Application 19277976Pending
Compositions And Methods For The Treatment Of Viral InfectionsMar 10, 2026 · US 12,569,565Granted
Fc Conjugates Including An Inhibitor Of CD73 And Uses ThereofJan 1, 2026 · Application 18880895Pending
Compositions And Methods For The Treatment Of Viral InfectionsSep 30, 2025 · US 12,427,200Granted
Protein-drug Conjugates For Antiviral TherapyAug 29, 2024 · Application 18281205Pending
Variant Fc Domains And Uses ThereofMay 30, 2024 · Application 18277911Pending
Methods For The Synthesis Of Protein-drug ConjugatesJan 25, 2024 · Application 18019855Pending
Methods For Preventing And Treating Intra-abdominal CandidiasisDec 21, 2023 · Application 18157307Pending
Compositions And Methods For The Treatment Of Viral InfectionsDec 5, 2023 · US 11,833,213Granted
Compositions And Methods For The Treatment Of Fungal InfectionsNov 21, 2023 · US 11,819,533Granted
Methods For The Synthesis Of Protein-drug ConjugatesNov 16, 2023 · Application 18019944Pending
Dosing Regimens For Treatment Of Fungal InfectionsAug 1, 2023 · US 11,712,459Granted
Compositions And Methods For The Treatment Of Bacterial InfectionsJun 22, 2023 · Application 16475809Pending
Single Dose Methods For Preventing And Treating Fungal InfectionsJun 15, 2023 · Application 17817537Pending
Compositions And Methods For The Treatment Of Bacterial InfectionsJun 1, 2023 · Application 16956011Pending
Dosing Regimens For Echinocandin Class CompoundsMay 23, 2023 · US 11,654,196Granted
Compositions And Methods For The Treatment Of Human Immunodeficiency VirusMar 16, 2023 · Application 17618335Pending
Compositions And Methods For The Treatment Of Respiratory Syncytial VirusMar 16, 2023 · Application 17618347Pending
Synthesis Of Echinocandin Antifungal AgentDec 13, 2022 · US 11,524,980Granted
Compositions And Methods For The Treatment Of Viral InfectionsNov 29, 2022 · US 11,510,992Granted
Variant Fc Domains And Uses ThereofJun 9, 2022 · Application 17675775Pending
Compositions And Methods For The Treatment Of Fungal InfectionsDec 14, 2021 · US 11,197,909Granted
Compositions And Methods For The Treatment Of Viral InfectionsJul 29, 2021 · Application 17193923Pending
Compositions And Methods For The Treatment Of Viral InfectionsJul 22, 2021 · Application 17194093Pending
Methods For Preventing Fungal InfectionsJan 7, 2021 · Application 16464493Pending
Methods For Preventing And Treating Pneumocystis InfectionsSep 22, 2020 · US 10,780,144Granted
Dosing Regimens For Echinocandin Class CompoundsJul 7, 2020 · US 10,702,573Granted
Methods For Preventing And Treating Intra-abdominal CandidiasisMay 28, 2020 · Application 16636083Pending
Methods For Treating Fungal InfectionsDec 12, 2019 · Application 16482043Pending
Single Dose Methods For Preventing And Treating Fungal InfectionsOct 10, 2019 · Application 16346424Pending
Methods For Preventing And Treating Pneumocystis InfectionsAug 6, 2019 · US 10,369,188Granted
Methods For Treating Fungal InfectionsSep 13, 2018 · Application 15760029Pending
Dosing Regimens For Echinocandin Class CompoundsJul 10, 2018 · US 10,016,479Granted
Antifungal Agents And Uses ThereofSep 7, 2017 · Application 15598913Pending
Antifungal Agents And Uses ThereofJun 13, 2017 · US 9,676,821Granted
Dosing Regimens For Echinocandin Class CompoundsDec 27, 2016 · US 9,526,835Granted
Compositions And Methods For The Treatment Of Fungal InfectionsJul 28, 2016 · Application 14916414Pending
Antifungal Agents And Uses ThereofDec 22, 2015 · US 9,217,014Granted
Fc Conjugates Including An Inhibitor Of CD73 And Uses ThereofApplication PCTUS2023026932Pending
Methods For Treating Influenza InfectionsApplication PCTUS2024018179Pending

GUILD ASSOCIATES INCSimilar federal contract value in Biotech · $69.6M in contracts
Spero Therapeutics, Inc.Similar federal contract value in Biotech · $65.6M in contracts
CRESTONE, INC.Similar federal contract value in Biotech · $61.5M in contracts
3D SystemsSimilar federal contract value in Biotech · $52.7M in contracts
Cempra PharmaceuticalsSimilar federal contract value in Biotech · $52.5M in contracts
Invirsa, Inc.Similar federal contract value in Biotech · $48M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.